Want real case studies? 10 seconds to sign up
Join the platform
Need Regulatory Help? Try Our Platform
Post your regulatory questions or request quotations from verified pharmaceutical consultants worldwide. Get matched with experts who specialize in your market.
April 4, 2026
Approximately 5 minutes
Licensed Pharmacist · Regulatory Affairs Consultant
Pharmacist, RA expert, and pharmaceutical & medical device SEO/GEO specialist.
Ask Anything
We'll follow up with you personally.
100% response rate • Reply within 7 business days
Related Articles
Approximately 5 minutes
U.S. FDA Office of New Drugs (OND) Organization, Functions, and Key Resources
The FDA’s Office of New Drugs (OND) within CDER reviews new drug and biologic applications, provides regulatory oversight for investigational studies, sets policy for efficient approvals, and maintains key databases such as Drugs@FDA and postmarket requirements, operating through eight review offices with 27 divisions focused on specific therapeutic areas.
Approximately 5 minutes
U.S. FDA Initiatives to Ensure Drug Supply Chain Integrity
The U.S. FDA safeguards the drug supply chain—one of the world’s safest—through the Drug Supply Chain Security Act (DSCSA) for electronic tracing, rapid reporting of illegitimate products, anti-counterfeiting guidance, public education campaigns like BeSafeRx and Know Your Source, and international partnerships to prevent counterfeit, stolen, or harmful drugs from reaching patients.
Approximately 5 minutes
U.S. FDA Drug Development and Approval Process Overview
The U.S. FDA’s Center for Drug Evaluation and Research (CDER) ensures marketed drugs are safe and effective by reviewing sponsor-submitted data in applications such as IND for clinical trials, NDA for new drugs, ANDA for generics, BLA for biologics, and OTC monographs or NDAs for nonprescription products.
Approximately 5 minutes
Harmonized Global Registration of a Class II Hemostatic Valve in Six Key Markets
A US medical device manufacturer successfully registered its Class II hemostatic valve in Australia, Brazil, China, India, Pakistan, and Russia by leveraging existing US, Canadian, and EU approvals and applying a harmonized regulatory strategy with core dossier preparation and efficient project management.
Approximately 5 minutes
Local Testing Support for Generic Radiopharmaceuticals During ANDA Registration in China
A global radiopharmaceutical manufacturer successfully completed mandatory local testing of two generic drugs at the official Chinese laboratory as part of its ANDA registration, overcoming challenges in sample importation, customs clearance, and analytical method transfer.